Skip to main content
Premium Trial:

Request an Annual Quote

Eli Lilly Business Team Staffer to Head SYN X s Development Efforts

NEW YORK, March 12 – Aaron Davidson, previously a member of Eli Lilly’s corporate development team, has been named vice president of business development at SYN X Pharma, the company said Monday.

SYN X, a Toronto-based proteomics company is looking to launch deals for therapeutics and diagnostics stemming from the company’s initiatives.

During his nine-year tenure with Eli Lilly, Davidson completed a number of multi-million dollar in- licensing, out-partnering, and distribution deals in the areas of epilepsy, Parkinson's disease, and oncology. 

At SYN X Davidson will be responsible for developing and accelerating strategic alliances for the company’s Proteomics Discovery Platform, which can be used to identify protein targets for the development of new drugs and antibody-based diagnostics. 

The company is currently developing diagnostics for diabetes, cardiovascular and central nervous system diseases.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.